 Connection
Austin Larson to Treatment Outcome
This is a "connection" page, showing publications Austin Larson has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.034 |
|
|
|
-
Kisanuki YY, Nobrega PR, Himes R, Jayadev S, Bernat JA, Prakash V, Gibson JB, Larson A, Sgobbi P, DeBarber AE, Murphy E, Fedor B, Wong Po Foo C, Dutta R, Imperiale M, Garner W, Quan J, Vig P, Duell PB, Perez S, Ramdhani RA, Saute JA. Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 study. Genet Med. 2025 Jul; 27(7):101449.
Score: 0.021
-
Starr MC, Chang IJ, Finn LS, Sun A, Larson AA, Goebel J, Hanevold C, Thies J, Van Hove JLK, Hingorani SR, Lam C. COQ2 nephropathy: a treatable cause of nephrotic syndrome in children. Pediatr Nephrol. 2018 07; 33(7):1257-1261.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|